Robert W. Baird upgraded shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) to a positive rating in a research note released on Monday morning. The firm currently has $24.00 price objective on the stock, up from their prior price objective of $20.00.
Other equities analysts have also issued reports about the company. TheStreet upgraded Diplomat Pharmacy from a d+ rating to a c- rating in a research note on Thursday, August 10th. Zacks Investment Research upgraded Diplomat Pharmacy from a sell rating to a hold rating in a research note on Wednesday, August 9th. BidaskClub lowered Diplomat Pharmacy from a hold rating to a sell rating in a research note on Monday, July 31st. Bank of America Corporation upped their target price on Diplomat Pharmacy from $17.00 to $18.50 and gave the company a neutral rating in a research note on Thursday, May 25th. Finally, Needham & Company LLC assumed coverage on Diplomat Pharmacy in a research note on Friday, July 21st. They issued a buy rating and a $19.75 target price for the company. One research analyst has rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $18.66.
Diplomat Pharmacy (NYSE DPLO) opened at 20.66 on Monday. Diplomat Pharmacy has a 12-month low of $12.25 and a 12-month high of $29.65. The stock has a market capitalization of $1.40 billion, a PE ratio of 112.90 and a beta of 0.65. The stock’s 50 day moving average price is $16.96 and its 200-day moving average price is $16.32.
Diplomat Pharmacy (NYSE:DPLO) last released its earnings results on Monday, August 7th. The company reported $0.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.10. The firm had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.14 billion. Diplomat Pharmacy had a return on equity of 7.97% and a net margin of 0.27%. The business’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.23 earnings per share. Analysts expect that Diplomat Pharmacy will post $0.75 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This report was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/09/21/diplomat-pharmacy-inc-dplo-raised-to-positive-at-robert-w-baird.html.
A number of large investors have recently made changes to their positions in DPLO. JPMorgan Chase & Co. increased its stake in Diplomat Pharmacy by 73.1% during the first quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock worth $116,000 after acquiring an additional 3,056 shares during the last quarter. State of Alaska Department of Revenue increased its stake in Diplomat Pharmacy by 80.0% during the second quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock worth $127,000 after acquiring an additional 3,833 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Diplomat Pharmacy by 46.7% during the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock worth $130,000 after acquiring an additional 2,794 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in Diplomat Pharmacy by 13.8% during the first quarter. BNP Paribas Arbitrage SA now owns 8,876 shares of the company’s stock worth $142,000 after acquiring an additional 1,073 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan increased its stake in Diplomat Pharmacy by 4.9% during the second quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock worth $152,000 after acquiring an additional 480 shares during the last quarter. Institutional investors own 69.89% of the company’s stock.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.